The combined positive score (CPS) of the programmed death ligand-1 (PD-L1) 22C3 assay is a predictive marker of pembrolizumab monotherapy for advanced esophageal cancer (EC) patients. We examined the association of the PD-L1 22C3 CPS with clinicopathological characteristics in 533 surgically resected EC specimens. Further, we independently compared 37 cases' different paraffin blocks of the same surgically resected specimen and 50 paired primary/metastatic lymph node lesions to investigate the heterogeneity of the PD-L1 expression. PD-L1 positive expression was positively associated with the presence of lymph node metastasis (59.2% chance, p = 0.021) and venous/lymphatic invasion (66.3% chance, p = 0.029). PD-L1 expression was highly consistent in different paraffin blocks of the same surgically resected specimen (p = 0.000016) and a moderate consistency (p = 0.000373) for the primary and metastatic lymph node lesion comparison. This is the novel study to demonstrate a positively correlation between a high PD-L1 22C3 CPS and invasion/metastasis risk in EC surgical specimens. Both paired blocks and paired primary/metastatic lymph node lesions showed significant concordance.

In this study involving 302 patients, EBUS-TBNA performed under conscious sedation with meperidine and midazolam led to 85% exams with adequate samples, of whom 62% were diagnostic and 38% showed normal lymph node tissue. A total of 12% were inadequate and 3% of scheduled exams were not performed. Severe and persistent adverse events have not been observed. A total of 94.4% of patients declared that they strongly agree to repeat the exam if necessary.

We developed a nomogram model for extensive-stage small cell lung cancer to calculate individual survival. The results confirmed that a first-line treatment paradigm of immune checkpoint inhibitors combined with chemotherapy prolongs overall survival.

Psoas major cross-sectional area / height squared less than 6.36 for men and less than 3.92 for females was defined as sarcopenia. Sarcopenia was a predictor of ILD exacerbation by chemotherapy. The prognosis for the sarcopenia group was worse than that for the nonsarcopenia group. Treatment targeting sarcopenia may be a breakthrough in lung cancer with ILD.

Apatinib maintenance therapy showed promising efficacy and safety to extend the OS/PFS of patients with ED-SCLC, thus making it a potent therapeutic option in future clinical practice.

All 18 studies included reported a response rate between the WBRT+TKI and WBRT only groups. The combined result indicated that ORR in the WBRT+TKI group was superior to WBRT only with a statistical difference (OR = 2.67, 95% CI: 2.10–3.38, p < 0.05) under a fixed effect model.

Circ_0007385 regulates the proliferation, apoptosis and stemness of NSCLC cells via the miR-493-3p/RAB22A axis.

Schematic model of the circ_0026134/miR-3619-5p/CHAF1B axis in NSCLC progression. In NSCLC cells, circ_0026134 was overexpressed, and miR-0026134 overexpression reduced the level of miR-3619-5p. The downregulation of miR-3619-5p resulted in an increase in the level of CHAF1B. Finally, the upregulation of CHAF1B enhanced cell proliferation, migration, invasion, glycolysis and repressed apoptosis, and thus promoted NSCLC progression.

We retrospectively reviewed the medical records of consecutive patients with advanced NSCLC with ECOG-PS ≤1 treated with nivolumab. We evaluated the differences between nonlong-term survivors and long-term survivors and performed univariate and multivariate analyses of factors associated with long-term survival. ΔNLR <1 was a significant long-term survival factor compared to ΔNLR ≥1 in advanced NSCLC patients treated with nivolumab.

This retrospective study enrolled patients with ground-glass nodules (GGN) and developed a deep learning (DL)-based method by using sequential computed tomography imaging to differentiate benign from malignant GGN, and then compared the DL method with radiologists. The results showed that DL can achieve diagnostic performance on the par with or better than radiologists in identify pulmonary GGNs.

For patients who underwent lobectomy, CAT symptoms such as cough, excessive phlegm, chest tightness, breathlessness, limited activities, lack of confidence leaving home, sleep disturbance, and lack of energy deteriorated significantly in the first month after surgery and lasted in the second month. For patients with wedge resection, cough, excessive phlegm, chest tightness, breathlessness, and limited activities deteriorated significantly in the first month after surgery and subsided in the second month.

Rechallenge with ICIs is less likely to result in a better response than initial ICI therapy. However, in the group of patients who achieved SD or better in the initial efficacy assessment after rechallenge with ICIs, ICI therapy can be continued for a longer period of time. This may be associated with prolonged survival.

Study aims and main results

We report a female lung adenocarcinoma patient (T3N2M1a) with brain metastases and possible coexistence of primary EGFR T790M mutation/EGFR exon 19 del/DCTN1-ALK translocation. The patient was sensitive to multiple treatment, including initial chemotherapy as well as the later administration of apatinib, osimertinib, and alectinib. We also summarize 22 published cases of lung adenocarcinoma patients with concurrent EGFR mutation and ALK rearrangement.

We present an extremely rare case of pseudomesotheliomatous manifestation of atypical carcinoid in a pregnant woman, focusing on the image findings and discrepancy between performance status and extensive metastasis. Our case shows that atypical carcinoids with multiple metastatic lesions can exhibit variability in vascularity and metabolism, resulting in heterogeneous image characteristics among metastatic lesions. In addition, even with extensive metastasis, patients can exhibit good performance explained by long-standing presentation of indolent cancer.

A single dose of pembrolizumab alone may be sufficient to cause durable response and serious immune-related adverse events in some cases.

A three-dimensional CT indicated that S8b subsegmentectomy was sufficient. The pulmonary artery was dissected to the A8a (white arrow) and b (black arrow) branches. This case demonstrated that early-stage metastatic clear cell renal carcinoma could recur after over 17 years. Thoracoscopic segmentectomy is less invasive and can preserve pulmonary function.